Science

Elpiscience is harnessing leading talent, innovation and resources with operations in both the U.S. and China to discover and develop the next generation of cancer immunotherapies. We have established comprehensive R&D capabilities including proprietary monoclonal and bispecific antibody discovery, translational research, clinical development, CMC and GMP manufacturing. Elpiscience has also assembled a global clinical team with a broad range of expertise from designing and leading first-in-human studies to executing large-scale global registration trials.

Immuno-Oncology Approach

Elpiscience aims to transform cancer treatment by developing immunotherapies to turn “cold” tumors “hot.” We strive to find differentiated biology to enable effective crosstalk between innate immunity and adaptive immunity, harnessing the full potential of the immune system to fight cancer.

Learn More
Translational Medicine

Elpiscience leverages our deep understanding of tumor biology and mechanisms of action to translate target biology for challenging pathways, develop biomarkers and strategically select indications and patients for clinical studies.  We apply cutting-edge technologies including gene editing for target screening, single cell sequencing and advanced bioinformatics with over 1,000 tumor organoid model collections that mimic the complex interaction between the human immune system and tumor microenvironment.

Clinical Development
Elpiscience has assembled a global clinical team with a broad range of expertise from designing and leading first-in-human studies to executing large-scale global registration trials.
Learn More
CMC Expertise and State-of-the-Art Manufacturing

Elpiscience’s seasoned CMC team and state-of-the-art manufacturing facility with 2x1000L cGMP capacity in Suzhou, China enables supply for up to 20 monoclonal and bispecific antibody production batches annually for Phase 1/2 clinical studies.

Learn More